Authors

Latest:

Dr. Sandler Discusses Hypofractionation in Prostate Cancer

Howard M. Sandler, MD, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses hypofractionation in prostate cancer.

Howard S. Hochster, MD

Latest:

Dr. Howard S. Hochster on TAS-102 Compared to 5FU

Howard S. Hochster, MD, professor of Medicine and Associate Director for Clinical Sciences, Yale Cancer Center, discusses the potential of TAS-102 for colorectal cancer.

Howard S. Hochster, MD, FACP

Latest:

Dr Hochster on the Importance of Clinical Trial Participation in Cancer Care

Howard S. Hochster, MD, discusses the importance of clinical trial participation for patients with cancer and highlights the use of precision medicine across the treatment armamentarium.

Howard S. Hochster, MD, FACP, Rutgers Cancer Institute of New Jersey

Howard S. Hochster, MD, Yale Cancer Center

Howard Sandler, MD, MS, FASTRO

Latest:

Dr. Sandler on Docetaxel With Hormonal and Radiation Therapy in Prostate Cancer

Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.

Howard "Skip" A. Burris, III, MD

Latest:

Dr. Burris on the Exploration of PARP Inhibitors in TNBC

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the exploration of PARP inhibitors in triple-negative breast cancer.

Howard "Skip" Burris, III, MD

Latest:

Dr. Burris on Molecular Profiling in Breast Cancer

Howard "Skip" A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the impact of molecular profiling in breast cancer.

Howard W. Follis, MD

Latest:

EHRs in the Urology Office

The implementation of electronic health records to replace paper charts in urology practices is a recent phenomenon that is picking up some serious momentum.

HRA

Latest:

Unraveling the Layers: IDNs, ACOs, and the Future of Healthcare Integration

This recorded webinar features thought leader perspectives and key insights from HRA's newest research program - Understanding Integrated Delivery Networks.

Hristos Kaimakliotis, MD

Latest:

Dr. Hristos Kaimakliotis on Predictive Markers in Bladder Cancer

Hsingwen Chung, BS Pharm, MS

Latest:

Treatment Patterns of Metastatic Triple-Negative Breast Cancer in US Community Practice Settings

First-line treatment patterns for metastatic triple-negative breast cancer are diverse, reflecting a lack of consensus and an unmet need for standardized therapy.

Hugo Ford, MD

Latest:

Dr. Ford on Docetaxel in Esophagogastric Cancer

Hugo Ford, MD, from the Addenbrooke's Hospital in Cambridge, UK, describes which patients with metastatic esophagogastric cancer derive the greatest benefit from second-line treatment with docetaxel.

Hugues Bourgeois, MD

Latest:

SABCS Interview Series

The January issue of OBTN featured highlights from the 32nd Annual San Antonio Breast Cancer Symposium (SABCS). We wrap up our SABCS coverage this month with interviews on denosumab with Alison Stopeck, MD, associate professor of medicine at the University of Arizona and director of the Clinical Breast Cancer Program at the Arizona Cancer Center; oral bisphosphonates with Rowan T.Chlebowski, MD, PhD, professor and chief of the Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center; and adjuvant chemotherapyÃƒÂ¢Ã¯Â¿Â½Ã¯Â¿Â½induced alopecia with Hugues Bourgeois, MD, Centre Jean Bernard in Lemans, France.

Hui-Kuo Shu, MD, PhD

Latest:

Advanced 3D MRI Technology Marks a Leap Forward in Glioblastoma Imaging

Although advances have been made in imaging techniques for patients with glioblastoma multiforme, new tools are needed to supplement standard imaging sequences.

Hui-Zi Chen, MD, PhD

Latest:

Dr. Chen on Rapid Research Autopsy in Rare Cancer

Hui-Zi Chen, MD, PhD, discusses the use of rapid research autopsy in metastatic ultra-hypermutated interdigitating dendritic cell sarcoma, an extremely rare cancer of dendritic origin that lacks a standardized treatment approach.

Huma Q. Rana, MD

Latest:

Dr. Rana on the Rationale for Video Genetic Counseling in Prostate Cancer

Huma Q. Rana, MD, MPH, discusses the rationale for the ProGen trial, which compared the effectiveness of video education versus in-person genetic counseling for men with prostate cancer.

Humberto Choi, MD

Latest:

Dr. Choi on Using Low-Dose CT Scans to Screen for Lung Cancer

Humberto Choi, MD, discusses using low-dose CT scans to screen patients with a high-risk of developing lung cancer.

Hun Ju Lee, MD

Latest:

Dr. Lee on Potential Challenges With VLS-101 in MCL and DLBCL

Hun Ju Lee, MD, discusses potential challenges with VLS-101 in mantle cell lymphoma and diffuse large B-cell lymphoma.

Hung T. Khong, MD

Latest:

Dr. Khong on the Importance of BRCA Testing in Breast Cancer

Hung Khong, MD, underscores the importance of testing for BRCA mutations in patients with breast cancer.